Bitte benutzen Sie diese Kennung, um auf die Ressource zu verweisen: https://doi.org/10.21256/zhaw-29657
Publikationstyp: Beitrag in wissenschaftlicher Zeitschrift
Art der Begutachtung: Peer review (Publikation)
Titel: Beneficial and harmful effects of tricyclic antidepressants for adults with major depressive disorder : a systematic review with meta-analysis and trial sequential analysis
Autor/-in: Kamp, Caroline Barkholt
Petersen, Johanne Juul
Faltermeier, Pascal
Juul, Sophie
Siddiqui, Faiza
Barbateskovic, Marija
Kristensen, Andreas Torp
Moncrieff, Joanna
Horowitz, Mark Abie
Hengartner, Michael Pascal
Kirsch, Irving
Gluud, Christian
Jakobsen, Janus Christian
et. al: No
DOI: 10.1136/bmjment-2023-300730
10.21256/zhaw-29657
Erschienen in: BMJ Mental Health
Band(Heft): 27
Heft: 1
Seite(n): e300730
Erscheinungsdatum: 2024
Verlag / Hrsg. Institution: BMJ Publishing Group
ISSN: 2755-9734
Sprache: Englisch
Fachgebiet (DDC): 615: Pharmakologie und Therapeutik
616.8: Neurologie und Krankheiten des Nervensystems
Zusammenfassung: Question: Tricyclic antidepressants are used to treat depression worldwide, but the adverse effects have not been systematically assessed. Our objective was to assess the beneficial and harmful effects of all tricyclic antidepressants for adults with major depressive disorder. Study selection and analysis: We conducted a systematic review with meta-analysis and trial sequential analysis. We searched CENTRAL, MEDLINE, Embase, LILACS and other sources from inception to January 2023 for randomised clinical trials comparing tricyclic antidepressants versus placebo or ‘active placebo’ for adults with major depressive disorder. The primary outcomes were depressive symptoms measured on the 17-item Hamilton Depression Rating Scale (HDRS-17), serious adverse events and quality of life. The minimal important difference was defined as three points on the HDRS-17. Findings: We included 103 trials randomising 10 590 participants. All results were at high risk of bias, and the certainty of the evidence was very low or low. All trials only assessed outcomes at the end of the treatment period at a maximum of 12 weeks after randomisation. Meta-analysis and trial sequential analysis showed evidence of a beneficial effect of tricyclic antidepressants compared with placebo (mean difference −3.77 HDRS-17 points; 95% CI −5.91 to −1.63; 17 trials). Meta-analysis showed evidence of a harmful effect of tricyclic antidepressants compared with placebo on serious adverse events (OR 2.78; 95% CI 2.18 to 3.55; 35 trials), but the required information size was not reached. Only 2 out of 103 trials reported on quality of life and t-tests showed no evidence of a difference. Conclusions: The long-term effects of tricyclic antidepressants and the effects on quality of life are unknown. Short-term results suggest that tricyclic antidepressants may reduce depressive symptoms while also increasing the risks of serious adverse events, but these results were based on low and very low certainty evidence.
URI: https://digitalcollection.zhaw.ch/handle/11475/29657
Volltext Version: Publizierte Version
Lizenz (gemäss Verlagsvertrag): CC BY-NC 4.0: Namensnennung - Nicht kommerziell 4.0 International
Departement: Angewandte Psychologie
Organisationseinheit: Psychologisches Institut (PI)
Enthalten in den Sammlungen:Publikationen Angewandte Psychologie

Dateien zu dieser Ressource:
Datei Beschreibung GrößeFormat 
2024_BarkholtKamp-etal_Effects-of-tricyclic-antidepressants-for-adults.pdf5.31 MBAdobe PDFMiniaturbild
Öffnen/Anzeigen
Zur Langanzeige
Kamp, C. B., Petersen, J. J., Faltermeier, P., Juul, S., Siddiqui, F., Barbateskovic, M., Kristensen, A. T., Moncrieff, J., Horowitz, M. A., Hengartner, M. P., Kirsch, I., Gluud, C., & Jakobsen, J. C. (2024). Beneficial and harmful effects of tricyclic antidepressants for adults with major depressive disorder : a systematic review with meta-analysis and trial sequential analysis. BMJ Mental Health, 27(1), e300730. https://doi.org/10.1136/bmjment-2023-300730
Kamp, C.B. et al. (2024) ‘Beneficial and harmful effects of tricyclic antidepressants for adults with major depressive disorder : a systematic review with meta-analysis and trial sequential analysis’, BMJ Mental Health, 27(1), p. e300730. Available at: https://doi.org/10.1136/bmjment-2023-300730.
C. B. Kamp et al., “Beneficial and harmful effects of tricyclic antidepressants for adults with major depressive disorder : a systematic review with meta-analysis and trial sequential analysis,” BMJ Mental Health, vol. 27, no. 1, p. e300730, 2024, doi: 10.1136/bmjment-2023-300730.
KAMP, Caroline Barkholt, Johanne Juul PETERSEN, Pascal FALTERMEIER, Sophie JUUL, Faiza SIDDIQUI, Marija BARBATESKOVIC, Andreas Torp KRISTENSEN, Joanna MONCRIEFF, Mark Abie HOROWITZ, Michael Pascal HENGARTNER, Irving KIRSCH, Christian GLUUD und Janus Christian JAKOBSEN, 2024. Beneficial and harmful effects of tricyclic antidepressants for adults with major depressive disorder : a systematic review with meta-analysis and trial sequential analysis. BMJ Mental Health. 2024. Bd. 27, Nr. 1, S. e300730. DOI 10.1136/bmjment-2023-300730
Kamp, Caroline Barkholt, Johanne Juul Petersen, Pascal Faltermeier, Sophie Juul, Faiza Siddiqui, Marija Barbateskovic, Andreas Torp Kristensen, et al. 2024. “Beneficial and Harmful Effects of Tricyclic Antidepressants for Adults with Major Depressive Disorder : A Systematic Review with Meta-Analysis and Trial Sequential Analysis.” BMJ Mental Health 27 (1): e300730. https://doi.org/10.1136/bmjment-2023-300730.
Kamp, Caroline Barkholt, et al. “Beneficial and Harmful Effects of Tricyclic Antidepressants for Adults with Major Depressive Disorder : A Systematic Review with Meta-Analysis and Trial Sequential Analysis.” BMJ Mental Health, vol. 27, no. 1, 2024, p. e300730, https://doi.org/10.1136/bmjment-2023-300730.


Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt, soweit nicht anderweitig angezeigt.